Compare · HCXY vs PHO
HCXY vs PHO
Side-by-side comparison of Hercules Capital, Inc. (HCXY) and Invesco Water Resources ETF (PHO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HCXY and PHO operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.56B.
- Over the past year, HCXY is down 0.5% and PHO is down 1.2% - HCXY leads by 0.7 points.
Invesco Water Resources ETF
The investment seeks to track the investment results (before fees and expenses) of the NASDAQ OMX US Water IndexSM (the "underlying index"). The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index seeks to track the performance of companies that create products designed to conserve and purify water for homes, businesses and industries. The underlying index may include common stocks, ordinary shares, American depositary receipts ("ADRs"), shares of beneficial interest and tracking stocks. The fund is non-diversified.
Latest HCXY
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call
- Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments
- Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS
- Hercules Capital Named 2025 Americas BDC Manager of the Year by Private Debt Investor
- Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029
Latest PHO
- Software Provider Roper Tech Boosts Annual Outlook Following Q1 Performance: The Details
- Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
- Photocure ASA: Results for the fourth quarter of 2023
- Photocure Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China
- Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
- Photocure to present at four investor conferences in November/December 2023
- Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
- Photocure ASA: Change of Board Composition
- Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
- Photocure ASA: Results for the second quarter and first half of 2023